Johnson & Johnson (JNJ) Offering Possible 40.45% Return Over the Next 16 Calendar Days

Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $140.00 short call and a strike $145.00 long call offers a potential 40.45% return on risk over the next 16 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $140.00 by expiration. The full premium credit of $1.44 would be kept by the premium seller. The risk of $3.56 would be incurred if the stock rose above the $145.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.

The RSI indicator is at 22.73 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Johnson & Johnson

Johnson & Johnson Strikes COVID-19 Vaccine Manufacturing Deal With South Africa's Aspen
Mon, 02 Nov 2020 11:20:37 +0000
Durban-based Aspen Pharmacare Holdings (OTC: APNHY) has preliminary agreed to commercially manufacture Pharmaceutical giant Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine candidate, Ad26.COV2-S, the company said in a statement.What Happened: According to Bloomberg, Aspen Pharmacare is Africa's biggest drugmaker and can produce 300 million doses a year.Aspen has agreed to commercially manufacture Johnson and Johnson's COVID-19 vaccine candidate at its Port Elizabeth plant, in which the company has invested $184 million.Aspen will perform formulation, filling, and secondary packaging of the vaccine.Why It Matters: South Africa has recorded 726,000 coronavirus infections, and it is hosting at least four clinical trials of potential COVID-19 vaccines, including the J&J candidate, reports Reuters.J&J had resumed the pivotal Phase 3 ENSEMBLE trial on Oct. 23 in the U.S. after a temporary pause. The trial was to test the safety and efficacy in adults aged between 18 and 60 years.According to Reuters, the company plans to test its vaccine in children aged between 12 and 18, subject to regulations soon.Rival drugmaker Pfizer Inc (NYSE: PFE) has already begun testing the messenger RNA (mRNA) vaccine in children as young as 12 years. J&J uses a cold virus to deliver coronavirus genetic material to spur an immune response. The company used the AdVac platform in Ebola vaccines as well.Price Action: J&J shares closed lower by 0.06% to $137.11 on Friday. Aspen Pharmacre shares have jumped 7.4% in Johannesburg on last check Monday. See more from Benzinga * Click here for options trades from Benzinga * Global Markets Today: Shares Retreat From Last Week's Losses * Facebook Fails At Curbing False Political Ads Ahead Of US Election: WSJ(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

J&J Strikes Covid-19 Vaccine Manufacturing Deal With Aspen
Mon, 02 Nov 2020 10:02:01 +0000
Johnson & Johnson has struck a preliminary agreement with Aspen Pharmacare Holdings to manufacture its Covid-19 vaccine candidate Ad26.COV2-S at a factory in South Africa, which has a capacity to produce more than 300 million doses a year.The agreement is still subject to the successful completion of relevant technology transfer and finalisation of commercial manufacturing terms. As part of the deal, Aspen Pharmacare will perform formulation, filling and secondary packaging for the supply of J&J’s (JNJ) vaccine.Ad26.COV2-S is currently undergoing clinical trials after they were briefly halted last month following a serious illness in a study participant. On Oct. 23, J&J announced that it is preparing to resume the Phase 3 US trial of its Covid-19 vaccine candidate, after “no evidence” was found that the vaccine caused the illness.“We have invested globally in our sterile capability and are determined to play a role in the manufacture of vaccines,” said Aspen CEO Stephen Saad. “We have been selected as a vaccine partner by Johnson & Johnson and this project will receive priority focus.”Saad added that Aspen has been a global supplier for antiretrovirals for the treatment of HIV/AIDS, multi-drug-resistant-TB products and Covid-19-related treatments such as anaesthetics and dexamethasone.Shares of JNJ are down 6% year-to-date, and the stock scores a bullish Strong Buy Street consensus. That’s with 4 back-to-back Buy ratings over the last three months. Meanwhile the average analyst price target of $169 indicates 23% upside potential lies ahead.On Oct. 14, Cantor Fitzgerald analyst Louise Chen raised the stock's price target to $180 (31% upside potential) from $168 and maintained a Buy rating, saying that J&J’s recent Q3 EPS and sales beat, reflect solid performance and positive trends across its diversified business model.Commenting on last month’s Covid-19 vaccine trial pause, Chen said that although it was creating some noise, it did not change her investment thesis on the company. (See JNJ stock analysis on TipRanks)Related News: Moderna Scores $1.1B From Covid-19 Vaccine Deposits; Shares Rise 3% Opko Health Tanks 10% Despite Solid Q3 Covid Testing Revenue Gilead Cuts 2020 Guidance As Remdesivir Sales Disappoint More recent articles from Smarter Analyst: * Alibaba-Backed XPeng Records 229% Rally In EV Deliveries; Stock Up 8% * Lear's 3Q Profit Crushes Estimates Amid Car Production Rebound * Sanofi Inks Deal To Snap Up Kiadis For $359M; Street Bullish * Mohawk Surges 11% On 3Q Results; Street Says Hold

South Africa's Aspen agrees initial deal to make J&J vaccine candidate
Mon, 02 Nov 2020 07:37:51 +0000
South African pharmaceutical company Aspen Pharmacare said on Monday it had reached a preliminary agreement with Johnson & Johnson to commercially manufacture its COVID-19 vaccine candidate, sending its shares higher. The country's biggest drugmaker said it had agreed to provide capacity required for the manufacture of J&J's vaccine candidate, which is still in clinical trials, at its Port Elizabeth facility.

South Africa's Aspen agrees with J&J to manufacture COVID-19 vaccine candidate
Mon, 02 Nov 2020 07:35:05 +0000
South African pharmaceutical company Aspen Pharmacare said on Monday it had entered into a preliminary agreement with Johnson & Johnson to commercially manufacture its COVID-19 vaccine candidate. Aspen said it had agreed to provide capacity required for the manufacture of J&J's vaccine candidate, which is still undergoing clinical trials, at its Port Elizabeth facility.

2 Great Stocks to Buy No Matter Who Wins the Election
Sun, 01 Nov 2020 11:25:00 +0000
There's no sweating the results of the upcoming presidential race if you own shares of either of these companies.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.